Benzinga | Mar 4, 2021 08:08AM EST

JMP Securities Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $80

JMP Securities analyst Silvan Tuerkcan initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating and announces Price Target of $80.